ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

Rosen Law Firm has filed a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased common stock between July 30, 2025 and February 24, 2026. The lawsuit alleges that Beta Bionics made materially false and misleading statements about its iLet Bionic Pancreas insulin pump, which the FDA found to be malfunctioning and dosing patients with dangerously high insulin levels. The company allegedly failed to disclose thousands of complaints and hundreds of life-threatening events to the FDA. The deadline for investors to serve as lead plaintiff is November 3, 2026.